 |
|
cediranib maleate
The maleate salt of an indole ether quinazoline derivative with antineoplastic activities. Competing with adenosine triphosphate, cediranib binds to and inhibits all three vascular endothelial growth factor receptor (VEGF-1,-2,-3) tyrosine kinases, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Recentin | | | | Foreign brand name: | | Recentin | | | | Code name: | | AZD2171 | | | | Chemical structure names: | | - 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1- yl)propoxy]quinazoline (2Z)-but-2-enedioate
- quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1- pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1)
| | |
|
|
